Cash Capital has returned for OnQuality Pharmaceuticals’s latest round, having already participated in a $15m series A in 2019.

OnQuality Pharmaceuticals, a US-based developer of drugs to counteract chemotherapy side effects, secured $20m in series A-plus financing today from investors including Cash Capital, the investment arm of Chinese Academy of Sciences.
Sinovation Ventures, Shiyu Capital, Matrix Partners China, BioTrack Capital and Frees Fund also took part, as did unnamed investors.
Founded in 2018, OnQuality is developing treatments drugs for patients undergoing cancer therapy that lessen side effects associated with current medications.
It will put the money towards clinical trials and preclinical pipeline development. Concurrently, Michael McCullar has been named as the company’s new chief executive.
OnQuality closed a $15m series A round in 2019 backed by Cash Capital, Matrix Partners China and BioTrack Capital.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.